Rani Therapeutics names Nicholas Maestas as CFO

Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) appointed Nicholas Maestas as Chief Financial Officer, effective immediately, according to a press release from the clinical-stage biotherapeutics company.

Maestas succeeds Svai Sanford, who announced his departure in May 2026 to pursue another professional opportunity. Talat Imran, Chief Executive Officer of Rani, cited Maestas's experience in biopharma capital markets and corporate strategy in a statement accompanying the announcement.

Maestas joins from Tempest Therapeutics, where he served as CFO and head of corporate strategy, leading financing transactions including registered direct offerings, PIPEs, and strategic mergers. Before that, he served as head of financial planning and analysis and strategic finance at Alector, where he supported a $2.2 billion global collaboration with GSK. Earlier in his career at Immune Design, he was involved in the company's $300 million acquisition by Merck.

Maestas holds an MBA in finance and health care management from the Wharton School at the University of Pennsylvania and a bachelor's degree in molecular and cell biology from the University of California, Berkeley. He brings more than 10 years of financial leadership experience at clinical-stage biotechnology companies.

You May Also Be Interested In

• Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
• Landstar names Bill Clement as chief commercial officer
• Microchip Technology to acquire edge AI chip firm Hailo